Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation. (3rd July 2022)

• Record Type: Journal Article
• Authors: Mazzawi, Tarek; Hausken, Trygve; El-Salhy, Magdy
• Is Part Of: Scandinavian journal of gastroenterology. Volume 57:Number 7(2022)
• Page Start: 792
• Page End: 796
• Publication Date: 2022-07-03
• Subjects: Colon -- enteroendocrine cells -- fecal microbiota transplantation -- immunohistochemistry -- irritable bowel syndrome; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2022.2036809
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Objectives: The aim was to investigate the effect of fecal microbiota transplantation (FMT) on colonic enteroendocrine cells densities in patients with irritable bowel syndrome (IBS). Materials and methods: This study is connected to the REFIT study, a double-blinded placebo-controlled trial to investigate using FMT for IBS treatment. Eighty-three subjects received either donor-FMT or placebo FMT (own feces) by colonoscope to cecum. Biopsies were obtained from sigmoid colon. Ten responders and ten non-responders consented to new biopsy one-year after FMT. Sixteen patients received donor-FMT and four received placebo FMT. Biopsies were immunostained for all of the colonic enteroendocrine cells and were quantified using computerized image analysis. Allocation sequence was revealed after obtaining re-biopsies and cells quantification. Results: Scores for IBS-SSS (mean ± SEM) of responders (eight of 10 patients who received donor FMT) and non-responders changed from baseline to one year after FMT (297 ± 11 and 81 ± 16, p < .0001, and 270 ± 17 and 291 ± 16, p = .15, respectively). Using paired t -test to compare enteroendocrine cells densities one-year after FMT to baseline showed significant increase only in somatostatin immunoreactive cells density in the total IBS responders group ( p = .023) and who received donor-FMT ( p = .038). The densities of peptide YY and enteroglucagon immunoreactive cells increased significantly ( p = .04 and .035, respectively) in donor-FMT recipients. No significant changes were noted in placebo FMT or nonresponders subgroups. Conclusion: This study shows that colonic enteroendocrine cells densities significantly change in responders group that received donor-FMT. The mechanisms for the cross talks between gut microbiota and colonic enteroendocrine cells remain to be investigated.